-

Accellix Expands its Leadership Team

SAN JOSE, Calif. & JERUSALEM--(BUSINESS WIRE)--Accellix Inc. is pleased to announce that Terrance Gin is joining its leadership team as Vice President Global Operations effective immediately.

Terrance brings over 30 years of management experience in IVD manufacturing, process and product development, clinical laboratory operations, quality assurance, capital improvement, facility, and EH&S. He was VP of Operations at Singulex in charge of building the operational functions supporting the growth of RUO and clinical testing businesses and Senior Director of Manufacturing at Cepheid responsible for instrument and consumable production. He has recently worked as the Engineering Leader at Becton Dickinson and Thermo Fisher Scientific, improving, and scaling up their production processes and equipment. Over the course of his career, Terrance has worked with flow cytometry, microfluidics, lateral flow, PCR and automated laboratory and manufacturing systems. He holds a BS in Chemistry from UC Berkeley and a MS in Chemical Engineering from San Jose State University.

Nir Nimrodi, Chairman and CEO, said: “Our company is rapidly growing. From supporting 2 customers two years ago, we are now supporting more than 20 leading biopharmaceutical companies in their efforts to develop lifesaving cell therapies. As the number of customers is expected to continue growing, we wish to elevate the quality of everything that we do even further. “

Terrance commented, “Having spent a good portion of my career scaling up operations and launching products in the demanding life science space, I recognize the strong connection between a clear market need and the great solution that Accellix is presenting. I am excited to join Accellix’s strong team in the pursuit of enabling our customers to achieve their goals.”

In addition to the expansion of the leadership team, Accellix added a new role of VP Products. Reed Hickey, who has served as Vice President Operations until now, will assume this new role.

Reed added: “Our future growth will benefit from accelerating the launch of our custom and catalog products. I will operate with the goal of turning the Accellix Platform into the cell therapy gold standard. We are currently developing more than twenty assays that will allow for the migration from traditional flow cytometers to the Accellix Cartridge Based Platform. The faster we can accomplish this effort, the faster our customers will benefit from a streamlined and automated quality control process for their cell therapies. “

Contacts

Accellix Inc.


Release Versions

Contacts

Social Media Profiles
More News From Accellix Inc.

Accellix Platform Chosen by the American Red Cross for Rapid and Accurate Allogeneic Source Material Characterization for Cell Therapy Development

SAN JOSE, Calif. & WASHINGTON--(BUSINESS WIRE)--The American Red Cross Cell and Gene Therapy Solutions (CGTS) division, a leading single-source provider for allogeneic cell therapy source material, has selected Accellix, Inc., the developer of the point-of-need testing automated flow cytometry platform, to provide Accellix instruments and assays at its CGTS collection sites to improve characterization of source materials used for cell therapy development. As the cell therapy industry continues...

Accellix Appoints Greg Hamilton as Chief Executive Officer as Company Accelerates Growth in Cell Therapy and Blood Bank Markets

SAN JOSE, Calif. & JERUSALEM--(BUSINESS WIRE)--Accellix, Inc., the leading sample to answer flow cytometry GMP platform company, is pleased to announce the appointment of Greg Hamilton as Chief Executive Officer and member of the Board effective September 23, 2024. He brings over 25 years of management experience in molecular diagnostics, life science tools, manufacturing and professional service industries as the company ramps growth in cell therapy and blood banks. In conjunction with Mr. Ham...

Accellix Raises $10 Million From BroadOak Capital Partners

SAN JOSE, Calif. & BETHESDA, Md.--(BUSINESS WIRE)--Accellix Inc., which provides quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use by cell therapy companies on the manufacturing floor and at the point-of-need, today announced that it has raised $10 million from BroadOak Capital Partners. BroadOak is known for its flexible growth capital and M&A advice for life sciences tools and services companies. The investment is part of BroadOak’s fifth fun...
Back to Newsroom